Abstract 543P
Background
Interstitial pneumonia (IP) is the common and poor prognostic comorbidities in patients with non-small cell lung cancer (NSCLC) and is a known risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. The aim of this study is to assess the incidence, severity and risk factors for pneumonitis induced by immune checkpoint inhibitor (ICI) monotherapy in NSCLC patients with idiopathic IP.
Methods
This is a multicenter, retrospective study in patients with (1) advanced or recurrent NSCLC, (2) comorbid idiopathic IP, and (3) receiving ICI monotherapy as second-line or later therapy. All CTs at baseline and at the onset of pneumonitis were centrally adjudicated by a board-certified radiologist. We performed logistic regression analysis to identify risk factors for pneumonitis using clinical characteristics, laboratory data and radiological findings as variables.
Results
Sixty-five patients were analyzed, with a median age of 71 years, and 98.5% had a smoking history. Sixty percent received nivolumab, 21.5% received atezolizumab and 18.5% received pembrolizumab. The median cycle of ICI was 4 cycles. Radiological patterns of IP were UIP (11%), probable UIP (15%), indeterminate for UIP (51%), alternative (23%), respectively, with 23% having honeycomb lung and a median %FVC of 95%. The incidence of pneumonitis was 23.1% for all grade and 13.9% for ≥grade3. We could not identify any significant risk factors for ICI-induced pneumonitis in the multivariate logistic regression analysis. There was no difference in the incidence and severity of ICI-induced pneumonitis when comparing patients with and without honeycomb lung, or with FVC ≥80% and <80%.
Conclusions
There was no difference in the risk of ICI-induced pneumonitis according to specific findings, including the radiological pattern of comorbid IP, the presence of honeycomb lung, and pulmonary function tests. ICIs should be carefully administrated in NSCLC with any types of comorbid IP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Ono, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Ono, Bristol Myers Squibb, Taiho, Eli Lilly, Pfizer, Boehringer Ingelheim, Takeda; Financial Interests, Personal, Research Grant: AstraZeneca, Chugai. J. Sakakibara-Konishi: Financial Interests, Personal, Research Grant: eli Lilly. K. Yokoo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Eli Lilly, Kyowa Kirin, MerckBiopharma, Novartis, Terumo, Takeda, Nippon Kayaku, Bristol Myers Squibb. T. Iwasawa: Financial Interests, Personal, Advisory Board: CANON Medical Systems, Ziosoft I; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim. T. Misumi: Financial Interests, Personal, Invited Speaker: Miyarisan. T. Ogura: Financial Interests, Personal, Invited Speaker: Japanese Boehringer Ingelheim, Shionogi; Financial Interests, Personal, Advisory Board: BMS, Japanese Boehringer Ingelheim, Taiho, Shionogi. All other authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract